Loading...
Market
What will be Myricx Pharma's next major milestone in NMTi-ADC therapeutics development by end of 2024?
2
Resolution / Starting Odds
Initiation of Phase 1 clinical trials • 25%
Publication of preclinical study results • 25%
Securing additional funding • 25%
Partnership with a major pharmaceutical company • 25%
Official announcements from Myricx Pharma or clinical trial registries
Story
London-Based Myricx Pharma Raises £90 Million in 2024 Series A for Cancer Drug Development
Jul 8, 2024, 05:42 AM
British biotech spinout Myricx Pharma, based in London, has successfully raised £90 million ($115 million) in a series A financing round in 2024. The funding, which is one of the largest in recent years in the UK, includes contributions from investors such as the controlling shareholder of Ozempic maker Novo Nordisk and SofinnovaVC. The capital will be utilized to advance Myricx's novel N-myristoyltransferase (NMT) inhibitor antibody-drug conjugates (NMTi-ADC) therapeutics into clinical development. CEO Robin Carr highlighted the company's innovative NMT payload approach to ADCs. This significant investment underscores the growing interest and commitment to cancer treatment advancements.
View original story
Similar markets
Initiate clinical trial • 25%
Secure additional funding • 25%
Enter partnership • 25%
Other • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Completion of Phase 3 trial • 25%
FDA approval • 25%
Partnership with another company • 25%
No major milestone announced • 25%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%
Phase III trial initiation • 25%
FDA accelerated approval • 25%
New interim data release • 25%
Other milestone • 25%
FDA Approval • 25%
EMA Approval • 25%
Additional Phase 3 Trials • 25%
Other • 25%
Trial halted • 25%
Limited efficacy • 25%
Moderate efficacy • 25%
High efficacy • 25%
Phase 2 Completion • 25%
Partnership/Acquisition • 25%
FDA Approval • 25%
Other • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
BLA submission • 25%
Phase III trial initiation • 25%
Conditional approval • 25%
No progress • 25%